Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional

An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Lantheus Germany GmbH

Enrolment target

169

Start

24 Aug 2022

ATTR Amyloidosis AL Amyloidosis Cardiac Amyloidosis

What is this study about?

The co-primary efficacy variables will be the sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (2)

—
Spain
—
Germany

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.